脑脊液髓系微囊泡可预测多发性硬化病程
结果显示微囊泡在神经炎症患者中升高,可鉴别复发缓解型多发性硬化与对照,并独立预测复发缓解型患者未来疾病活动及进展型患者残疾累积。
要点
- 脑脊液髓系微囊泡是神经炎症和微胶质/巨噬细胞活性的体内标志物。
- 微囊泡可鉴别复发缓解型多发性硬化与对照,并可区分放射学孤立综合征与非特异性脑病变。
- 微囊泡独立预测复发缓解型患者未来疾病活动及进展型患者残疾累积。
核心结论
- 脑脊液髓系微囊泡是神经炎症和微胶质/巨噬细胞活性的临床有意义生物标志物,可能辅助诊断和预后评估。
研究设计与样本
- 在诊断时收集所有患者的临床、人口学和MRI数据,并对176例患者进行随访。
主要发现
- 神经炎症患者脑脊液髓系微囊泡高于神经退行性和对照组。
- 多发性硬化患者中,有MRI疾病活动者微囊泡更高,且浓度随强化病灶数量增加而升高(p < 0.0001,Jonckheere-Terpstra检验)。
- 诊断前1个月和1年内疾病活动度更高的患者微囊泡也更高。
- 微囊泡鉴别复发缓解型与对照的AUC=0.939(p < 0.0001),鉴别放射学孤立综合征与非特异性脑病变的AUC=0.942(p < 0.0001)。
- 微囊泡独立预测复发缓解型患者未来疾病活动(HR=1.967,95%CI=1.147-3.372),并独立预测进展型患者残疾累积(HR=10.767,95%CI=1.335-86.812)。
临床怎么用
- 脑脊液髓系微囊泡检测或可用于多发性硬化的诊断工作流程和预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In vivo measures of myeloid activity are promising biomarkers in multiple sclerosis. We previously demonstrated that cerebrospinal fluid (CSF) myeloid microvesicles are markers of microglial/macrophage activity and neuroinflammation in multiple sclerosis. Here, we aimed at investigating the diagnostic and prognostic value of myeloid microvesicles in a clinical setting. METHODS: Six hundred one patients discharged with a diagnosis of neuroinflammatory, neurodegenerative, or no neurological disease were enrolled. Myeloid microvesicles were measured with flow cytometry as isolectin B4-positive events in fresh CSF. Clinical, demographical, and magnetic resonance imaging (MRI) data were collected at diagnosis (all patients) and during follow-up (n = 176). RESULTS: CSF myeloid microvesicles were elevated in neuroinflammatory patients compared to the neurodegenerative and control groups. In multiple sclerosis, microvesicles were higher in patients with MRI disease activity and their concentration increased along with the number of enhancing lesions (p < 0.0001, Jonckheere-Terpstra test). CSF myeloid microvesicles were also higher in patients with higher disease activity in the month and year preceding diagnosis. Microvesicles excellently discriminated between the relapsing-remitting and control groups (receiver operator characteristic curve, area under the curve = 0.939, p < 0.0001) and between radiologically isolated syndrome and unspecific brain lesions (0.942, p < 0.0001). Furthermore, microvesicles were independent predictors of prognosis for both the relapsing-remitting and progressive groups. Microvesicles independently predicted future disease activity in relapsing-remitting patients (hazard ratio [HR] = 1.967, 95% confidence interval [CI] = 1.147-3.372), correcting for prognostic factors of standard clinical use. In the progressive group, microvesicles were independent predictors of disability accrual (HR = 10.767, 95% CI = 1.335-86.812). INTERPRETATION: Our results confirm that CSF myeloid microvesicles are a clinically meaningful biomarker of neuroinflammation and microglial/macrophage activity in vivo. These findings may support a possible use in clinical practice during diagnostic workup and prognostic assessment. ANN NEUROL 2021;90:253-265.
引用
- Gelibter S, Pisa M, Croese T, et al. Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. Ann Neurol. 2021. PMID: 34216397. doi:10.1002/ana.26154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。